

1. Record Nr.	UNINA9910842297403321
Autore	Dorobantu Maria
Titolo	Hypertension and Heart Failure : Epidemiology, Mechanisms and Treatment
Pubbl/distr/stampa	Cham : , : Springer International Publishing AG, , 2024 ©2023
ISBN	3-031-39315-5
Edizione	[2nd ed.]
Descrizione fisica	1 online resource (523 pages)
Collana	Updates in Hypertension and Cardiovascular Protection Series
Altri autori (Persone)	VoicuVictor GrassiGuido Agabiti-RoseiEnrico ManciaGiuseppe
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Intro -- Introduction -- Contents -- Part I: Epidemiology of Hypertension and Hypertensive Heart Disease -- 1: Epidemiological Aspects: Prevalence and Risk of Heart Failure Related to Blood Pressure -- 1.1 The Prevalence and Incidence of Heart Failure (HF) -- 1.1.1 Heart Failure Definition and Classification -- 1.1.2 The Prevalence of Heart Failure -- 1.1.3 The Incidence of Heart Failure -- 1.1.4 Secular Trends in Heart Failure Epidemiology -- 1.1.5 Heart Failure Epidemiology in Middle- and Low-Income Countries -- 1.1.6 Mortality in Heart Failure -- 1.2 The Epidemiology of Hypertension and Heart Failure -- 1.3 Conclusions -- References -- 2: An Update on the Prevalence of Heart Failure -- 2.1 Introduction -- 2.2 Definition of HF and Its Changes -- 2.2.1 Lifetime Risk -- 2.2.2 Prevalence -- 2.3 Heart Failure with a Reduced Versus a Preserved Ejection Fraction -- 2.4 Asymptomatic Left Ventricular Dysfunction (ALVD) -- 2.5 Future Directions -- References -- 3: Heart Failure in Severely Hypertensive Children -- 3.1 Introduction -- 3.2 Severe Hypertension and Heart Failure -- 3.2.1 The Etiology of Severe Hypertension in Children and Adolescents -- 3.2.2 Clinical Presentation -- 3.2.3 Initial Investigations -- 3.2.4 Imaging Studies --

3.2.5 Mechanisms -- 3.2.6 Treatment -- 3.3 Conclusions --  
References -- Part II: Mechanisms of Heart Failure in Arterial  
Hypertension -- 4: Genetics of Hypertension and Heart Failure -- 4.1  
Heritability of Hypertension and Heart Failure -- 4.2 Genetics  
of Hypertension and Heart Failure -- 4.2.1 Sodium and Intravascular  
Volume -- 4.2.1.1 Monogenic Hypertension Syndromes -- 4.2.1.2  
Monogenic Hypotension Syndromes -- 4.2.1.3 Polygenic Pathways --  
4.2.2 Vascular Mechanisms -- 4.2.3 The Autonomic Nervous System  
-- 4.2.4 Cardiomyopathies -- 4.2.5 Mendelian Randomization (MR)  
Studies.  
4.2.6 Future Directions -- References -- 5: High Heart Rate:  
A Predictor of Heart Failure in Healthy Subjects and a Risk Factor  
for Adverse Outcome in Patients with Heart Failure -- 5.1 Introduction  
-- 5.2 High Heart Rate As A Risk Factor for the Development of Heart  
Failure -- 5.2.1 High Heart Rate: A Risk Factor or a Marker of Disease?  
-- 5.3 Association of High Heart Rate with Adverse Outcomes  
in Patients with Congestive Heart Failure -- 5.4 The Effect of Heart  
Rate Reduction in Patients with Heart Failure -- 5.4.1 The Effect  
of Beta-Blockers in Patients with a Preserved Left Ventricular Function  
-- 5.4.2 Ivabradine as a Heart Rate-Lowering Agent in Patients with HF  
-- 5.4.3 Use of Beta-Blockers in HF Patients with Atrial Fibrillation --  
5.5 Summary and Conclusions -- References -- 6: Blood Pressure  
Variability and Heart Failure: Pathophysiological and Clinical Aspects --  
6.1 Introduction -- 6.2 Relationship of BPV with Preclinical Cardiac  
Organ Damage -- 6.2.1 Very Short-Term BPV -- 6.2.2 Short-Term  
BPV -- 6.2.3 Mid-Term BPV -- 6.2.4 Long-Term BPV -- 6.3  
Relationship of BPV with Development of Heart Failure -- 6.3.1 Long-  
Term BPV -- 6.4 The Relationship of BPV with Outcomes in CHF  
Patients -- 6.4.1 Very Short-Term BPV -- 6.4.2 Short-Term BPV --  
6.4.3 Long-Term BPV -- 6.5 The Paradoxical Prognostic Value of BPV  
in CHF -- 6.6 Mechanisms of the Relationship Between BPV and CHF --  
6.7 Implications for Treatment -- 6.8 Conclusions -- References -- 7:  
Hemodynamic Markers in the Progression from Hypertension to Heart  
Failure -- 7.1 Introduction -- 7.2 LV Remodeling and Hypertrophy --  
7.3 LV End-Diastolic Filling Pressure (Diastolic Function) -- 7.4 LV  
Deformation -- 7.4.1 Changes in LV Longitudinal Strain in Response  
to an Increased Afterload -- 7.4.2 Changes in LV Radial Strain  
in Response to an Increased Afterload.  
7.5 The Correlation Network of BP and LV Traits -- 7.6 Assessment  
of LV and Arterial Elastance -- 7.7 Noninvasive Indexes of LV  
Myocardial Work from Pressure-Strain Loops -- 7.8 Conclusions --  
References -- 8: Sympathetic Activity in Hypertension and Heart Failure  
-- 8.1 Introduction -- 8.2 Sympathetic Nervous System Activation  
in Human Hypertension -- 8.2.1 Neural Reflex Mechanisms  
in the Pathogenesis of Hypertension -- 8.2.2 Interaction Between  
the Sympathetic Nervous System and the Renin-Angiotensin System --  
8.2.3 Central Neural Activation in Hypertension -- 8.2.4 The Link  
Between Hypertension and Heart Failure -- 8.3 Sympathetic Nervous  
System Activation in Heart Failure -- 8.3.1 The Role of the Kidneys  
in the Pathophysiology of Heart Failure -- 8.3.2 Neural Reflex  
Mechanisms in the Pathogenesis of Heart Failure -- 8.4 Device-Based  
Therapeutic Interventions -- 8.4.1 Renal Denervation (RDN)  
in Hypertension -- 8.4.2 Renal Denervation in Heart Failure -- 8.4.3  
Baroreflex Activation Therapy (BAT) in Hypertension -- 8.4.4  
Mechanical Endovascular Baroreflex Amplification -- 8.5 Baroreflex  
Activation Therapy in Heart Failure -- 8.6 Carotid Body Denervation  
in Hypertension -- 8.7 Carotid Body Denervation in Heart Failure --  
8.8 Future Directions -- References -- 9: Renal and Heart Failure

Interrelationship in Hypertension -- 9.1 Introduction -- 9.2  
Epidemiology -- 9.3 Mechanisms of Heart Failure and Kidney  
Dysfunction -- 9.3.1 Hemodynamics -- 9.3.2 Neurohumoral  
Mechanisms -- 9.3.3 Cardiovascular-Associated Mechanisms -- 9.4  
Clinically Relevant Issues -- 9.4.1 Comorbidities -- 9.4.2 Atrial  
Fibrillation (AF) and Progression in Renal Dysfunction -- 9.4.3 Acute  
Kidney Injury -- 9.4.4 Anemia -- 9.5 Treatment -- References -- 10:  
The Role of Uric Acid in Hypertension and Heart Failure.  
10.1 The Pathophysiology of Hyperuricemia and Cardiovascular  
Diseases -- 10.2 The Role of Inflammation in Gout and Cardiovascular  
Diseases -- 10.3 Hyperuricemia, Hypertension, Heart Failure,  
and Cardiovascular Disease -- 10.4 The Role of Hyperuricemia  
in Hypertension and Implications for Heart Failure -- 10.5 The Role  
of Hyperuricemia in Heart Failure -- 10.6 The Cardiovascular Benefits  
of Treating Hyperuricemia -- 10.6.1 Xanthine Oxidase Inhibitors --  
10.6.2 Sodium Glucose Cotransporter 2 Inhibitors (SGLT2-I) -- 10.6.3  
ARNI -- 10.6.4 Vericiguat -- 10.7 Conclusions -- References -- 11:  
Myocardial Ischemia: A Link Between Hypertension and Heart Failure --  
11.1 The Link Between Hypertension and Myocardial Ischemia -- 11.2  
The Link Between Myocardial Ischemia and Heart Failure -- 11.3  
Conclusions -- References -- 12: Role of Endothelial Dysfunction  
in the Progression from Hypertension to Heart Failure -- 12.1  
Endothelial Function -- 12.2 The Cardiometabolic Disease: Focus  
on the Microcirculatory System -- 12.3 Determinants of Endothelial  
Dysfunction in Hypertension and Their Role in the Progression to Heart  
Failure -- 12.3.1 Microvascular Inflammation -- 12.3.2  
Cyclooxygenase-2 -- 12.3.3 Mineralocorticoid Receptor -- 12.3.4  
Sphingolipid Metabolism and Sortilin -- 12.4 The Progression to HFpEF  
-- 12.5 Conclusions -- References -- 13: Panendothelitis  
Due to the SARS COV 2 Infection: Consequences on Hypertension  
and Heart Failure -- 13.1 Differential Specific Characteristics of SARS  
CoV 2 and Pathogenic Consequences -- 13.1.1 Proximal Origin,  
Differential Genomic Characteristics -- 13.1.2 SARS-CoV-2 Virus  
Cellular Receptor -- 13.1.3 Pathogenesis -- 13.1.4 Pathogenesis  
Associated with the Five Phases -- 13.2 ACE2, Physiological Functions,  
Tissue Distribution, and Functional Correlations.  
13.2.1 ACE2, the Receptor for SARS-CoV-2 Virus -- 13.2.2 ACE2  
Receptor Polymorphism of SARS-CoV-2 and the Correlation  
with Clinical Forms of Covid-19 -- 13.2.3 Tissue Expression of ACE2  
-- 13.3 Vascular Endothelium and Its Functions as a Princeps Target  
in the Pathogenesis of Covid-19 Disease -- 13.3.1 Panendothelitis:  
The Pathogenic Basis Covid-19 Disease -- 13.3.2 Relevant  
Morphofunctional Characteristics of the Vascular Endothelium --  
13.3.3 The Endothelium and the Systemic Endothelial Dysfunction --  
13.3.4 Protection and Functional Restoration of the Endothelium  
in Covid-19 -- 13.3.5 Pharmacotherapy of Endothelial Dysfunction --  
13.3.6 The Effects of Antihypertensive Drugs on Endothelial  
Dysfunction and Inflammation in Covid-19 -- 13.3.6.1 The  
Inflammasome and Pharmacological Inhibitors -- 13.4 SARS-CoV-2  
and Cardiovascular Comorbidities. Common Link: Panendothelitis  
(Systemic Endothelitis) -- 13.4.1 Cardiovascular Consequences  
of SARS-CoV-2 Interaction with the ACE2 Receptor When There Are  
Pre-Existing Comorbidities and/or Conditions That Are Favoring This  
Reaction -- 13.4.2 Myocarditis or the Direct Viral Infection  
of the Myocardium with Variable Evidence of Inflammation in Covid-19  
Disease -- 13.4.3 Prevalence of Hypertension and Other Conditions  
as Risk Factors for Covid-19 Disease -- 13.4.4 Mechanisms  
of Cardiovascular Disorders in Covid-19 Disease -- 13.5 General

Conclusions -- References -- 14: Pathophysiology of Hypertensive Heart Disease -- 14.1 Introduction -- 14.2 Left Ventricular Hypertrophy -- 14.3 Abnormal Left Ventricular Geometric Patterns -- 14.4 Diastolic Dysfunction -- 14.5 Systolic Dysfunction -- 14.6 Future Directions -- References -- Part III: New Perspectives on Diagnosis of Heart Failure in Hypertensive Patients -- 15: Left Ventricular Diastolic Dysfunction -- 15.1 Introduction. 15.2 Pathophysiology of Diastolic Dysfunction.

---